ArticleEndocrine, metabolic & immune disorders drug targets2026
Decoding Preeclampsia and Obesity: The Role of Immune Responses and Natural Product Interventions.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPreeclampsia (PE) is a pregnancy-specific disorder with high cerebrocardiovascular risk. Obesity increases PE risk, but current monotherapy remains insufficient. Shared mechanisms and natural product-based interventions for PE regarding obesity are urgently needed.
methodsMendelian Randomization (MR) was used to investigate the causal relationship between PE and obesity, and datasets from GEO were analyzed. Differential expression, enrichment analysis, PPI network, and machine learning (random forests, SVM) were applied to identify characteristic shared genes, which were validated using external datasets. ROC curves assessed diagnostic efficacy. CIBERSORT analyzed immune infiltration. ITGB5 expression was further evaluated using the HPA database. Natural products targeting characteristic genes were predicted, followed by molecular docking and dynamics analysis.
resultsMR confirmed obesity as a causal risk factor for PE. GSE96985 and GSE2508 were core datasets. Sixty-nine common DEGs were enriched in muscle cell cytoskeleton pathways. Twenty-five characteristic genes were screened; six genes showed significant diagnostic efficacy. Immune infiltration suggested CD8+ T cells as a shared immune cell type. ITGB5 was highlighted. HPA confirmed high expression in the placenta and adipose tissue. Puerarin formed a stable complex with ITGB5 (docking energy: -5.92 kJ/mol), supported by molecular dynamics. DISCUSSION: ITGB5 may link PE and obesity via immune-metabolic crosstalk, with CD8+ T cell dysregulation potentially contributing to inflammation, oxidative stress, and endothelial dysfunction. Puerarin emerges as a promising natural agent.
conclusionThese findings suggest that ITGB5 is a candidate shared gene in PE-obesity comorbidity, and that puerarin is a promising natural agent. Given the bioinformatic nature, these conclusions are hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.